41.25 0.00 (0.00%)
After hours: 4:01PM EST
Previous Close | 41.75 |
Open | 41.70 |
Bid | 40.92 x 800 |
Ask | 46.84 x 800 |
Day's Range | 38.88 - 41.80 |
52 Week Range | 17.51 - 60.52 |
Volume | 82,375 |
Avg. Volume | 189,235 |
Market Cap | 1.722B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.50 |
AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences. Presentation DetailsConference: Cowen 41st Annual Health Care ConferenceFormat: Ovarian Cancer Panel discussion Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer Date: March 2, 2021Time: 12:50 p.m. ESTWebcast Link: The panel discussion will be available live to conference attendees Conference: Oppenheimer 31st Annual Healthcare ConferencePresenter: Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: March 16, 2021Time: 11:20 a.m. ESTWebcast Link: Available Here The live webcast of the Oppenheimer presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date. About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact: Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com Media Contact:Stephanie Ascher Managing DirectorStern Investor Relations, Inc.Stephanie.ascher@sternir.com
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021. Presentation DetailsConference: Citi 2021 Virtual Immuno-Oncology DayFormat: Group meeting with Andrew Baum and covering analyst Mohit BansalPresenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: February 17, 2021Time: 12:00 p.m. ESTWebcast Link: Available Here A live webcast will be available at the Events & Presentations section of the Company’s website. About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com. Investor Contact:Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com Media Contact:Stephanie AscherManaging DirectorStern Investor Relations, Inc.Stephanie.ascher@sternir.com
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...